Spirapril effects on heart remodeling in patients with mild to moderate arterial hypertension

Abstract

In total, 62patients with mild to moderate arterial hypertension underwent echocardiography and Doppler cardiography. For 12 weeks, all participants received spirapril, 6 mg/d. Spirapril therapy was associated with reduced left ventricular hypertrophy and pathological heart remodeling type number.

Keywords

• arterial hypertension
• remodeling
• left ventricular hypertrophy
• spirapril